<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379596</url>
  </required_header>
  <id_info>
    <org_study_id>D967LC00001</org_study_id>
    <nct_id>NCT04379596</nct_id>
  </id_info>
  <brief_title>Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)</brief_title>
  <acronym>DG-03</acronym>
  <official_title>A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2 Overexpressing Gastric Cancer (DESTINY-Gastric03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics,
      immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or
      in combination with chemotherapy and/or durvalumab in HER2-positive advanced/metastatic
      gastric/gastroesophageal junction (GEJ) adenocarcinoma patients.

      Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or durvalumab
      administered to subjects at the recommended phase 2 dose will show manageable safety and
      tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing.
      T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered
      to HER2-positive gastric/GEJ cancer patients who have not received prior treatment for
      advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the
      potential to become a therapeutic option for this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">January 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will consist of 2 phases: a dose escalation phase (Part 1) and a dose expansion phase (Part 2). Part 1 will enroll HER2-overexpressing (IHC 3+ or IHC 2+/ISH+), previously treated gastric or gastro-esophageal junction (GEJ) cancer patients, and Part 2 will enroll HER2-overexpressing patients who have not received prior treatment for metastatic disease.
In addition to safety and tolerability, this study will also assess ORR, DoR, DCR, OS, PFS and other measures of antitumor activity among treatment groups. Tumor evaluation using RECIST v1.1 will be conducted at screening and every 6 weeks until RECIST 1.1 objective disease progression or withdrawal of consent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Safety will be assessed for approximately 24 months from informed consent.</time_frame>
    <description>Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective Response Rate (ORR)</measure>
    <time_frame>An average of approximately 12 months.</time_frame>
    <description>Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Objective Response Rate (ORR)</measure>
    <time_frame>An average of approximately 12 months.</time_frame>
    <description>Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Safety will be assessed for approximately 24 months from informed consent.</time_frame>
    <description>Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>An average of approximately 18 months.</time_frame>
    <description>DOR is defined as the time from the date of first documented response until the date of documented progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>An average of approximately 18 months.</time_frame>
    <description>DCR is the percentage of subjects who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>An average of approximately 18 months.</time_frame>
    <description>PFS is the time from date of treatment assignment (Part 1) or date of randomization (Part 2) until the date of objective disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>An average of approximately 30 months.</time_frame>
    <description>OS is the time from date of treatment assignment (Part 1) or date of randomization (Part 2) until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181a in all arms</measure>
    <time_frame>An average of approximately 24 months.</time_frame>
    <description>Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for each dose level for T-DXd, total anti-HER2 antibody, MAAA-1181a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab</measure>
    <time_frame>An average of approximately 24 months.</time_frame>
    <description>Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of ADAs for T-DXd and durvalumab (in study arms including T-DXd and durvalumab)</measure>
    <time_frame>An average of approximately 24 months.</time_frame>
    <description>Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd and durvalumab.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd and 5-fluorouracil (5-FU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd and capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd and durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd and 5-FU or capecitabine and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, durvalumab and 5-FU or capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab, 5-FU/capecitabine, and cisplatin/oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, 5-FU or capecitabine, and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, 5-FU or capecitabine, and durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil (5-FU)</intervention_name>
    <description>5-FU: administered as an IV infusion</description>
    <arm_group_label>Arm 1A</arm_group_label>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_label>Arm 1E</arm_group_label>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_label>Arm 2C</arm_group_label>
    <arm_group_label>Arm 2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: administered orally</description>
    <arm_group_label>Arm 1B</arm_group_label>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_label>Arm 1E</arm_group_label>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_label>Arm 2C</arm_group_label>
    <arm_group_label>Arm 2D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab: administered as an IV infusion</description>
    <arm_group_label>Arm 1C</arm_group_label>
    <arm_group_label>Arm 1E</arm_group_label>
    <arm_group_label>Arm 2D</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin: administered as an IV infusion</description>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_label>Arm 2A</arm_group_label>
    <arm_group_label>Arm 2C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab: administered as an IV infusion</description>
    <arm_group_label>Arm 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan</intervention_name>
    <description>T-DXd: administered as an IV infusion</description>
    <arm_group_label>Arm 1A</arm_group_label>
    <arm_group_label>Arm 1B</arm_group_label>
    <arm_group_label>Arm 1C</arm_group_label>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_label>Arm 1E</arm_group_label>
    <arm_group_label>Arm 2B</arm_group_label>
    <arm_group_label>Arm 2C</arm_group_label>
    <arm_group_label>Arm 2D</arm_group_label>
    <other_name>DS-8201a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin: administered as an IV infusion</description>
    <arm_group_label>Arm 2A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female participants must be at least 18 years of age (20 years of age in
             Japan)

          2. Disease Characteristics:

        Locally advanced, unresectable, or metastatic disease Pathologically documented
        adenocarcinoma of the stomach or GEJ with HER2 overexpression (IHC 3+ or ICH 2+/ISH+) 3.
        For Part 1, progression on or after at least one prior trastuzumab-containing regimen For
        Part 2, previously untreated for unresectable or metastatic adenocarcinoma of the stomach
        or GEJ with HER2 overexpression.

        4. Has measurable target disease assessed by the Investigator based on RECIST version 1.1
        5. Has protocol- defined adequate organ function including cardiac, renal and hepatic
        function 6. If of reproductive potential, agrees to use a highly effective form of
        contraception or avoid intercourse during and upon completion of the study and for at least
        7 months (female) or 4 months (male) after last dose of study drug.

        Exclusion criteria:

          1. History of active primary immunodeficiency, known HIV, active HBV or HCV infection, or
             active tuberculosis.

          2. Uncontrolled intercurrent illness

          3. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that
             cannot be ruled out by imaging at screening

          4. Lung-specific intercurrent clinically significant severe illnesses

          5. Uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or
             antifungals

          6. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal
             shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART).

          7. Has spinal cord compression or clinically active central nervous system metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>HER2</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Deruxtecan</keyword>
  <keyword>T-DXd</keyword>
  <keyword>DS-8201a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Study start to completion date</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

